Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14
Skipping Mutation.
10.3779/j.issn.1009-3419.2023.102.19
- Collective Name:Editorial Office of Chinese Journal of Lung Cancer
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
MET exon 14 skipping mutation;
MET inhibitors;
Targeted therapy
- MeSH:
Humans;
Aged;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Consensus;
Proto-Oncogene Proteins c-met/genetics*;
Mutation;
Exons;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2023;26(6):416-428
- CountryChina
- Language:Chinese
-
Abstract:
The mesenchymal-epithelial transition factor (MET) exon 14 skipping mutation is mainly caused by the loss of c-Cbl tyrosine binding site. This mutation could result in a decrease in the degradation rate of proteasome-mediated MET proteins, trigger continuous activation of downstream pathways, and ultimately lead to tumorigenesis. The incidence of MET exon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC) is 0.9% to 4.0%. Patients with advanced NSCLC are recommended to test MET exon 14 skipping mutations who may benefit from MET inhibitors-targeted therapy. MET inhibitors have a high objective response rate and good safety profiles, which could prolong the survival of NSCLC patients with MET exon 14 skipping mutations. The Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized multidisciplinary experts to give suggestions on the important issues of clinical aspects for targeted therapy of MET exon 14 skipping mutation in NSCLC according to the clinical practice experiences and evidences based medicine. "Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation" is proposed, aiming to provide standardized guidances for the clinical practice of Chinese physicians.
.
